Emerging Trends and Innovations for the Gene Therapy Market | projected to reach USD 38.33 Billion by 2030

According to a research report "Gene Therapy Market”, By Technology (Viral Vector-Based Gene Therapy {Adeno-Associated Virus (AAV), Lentivirus, Adenovirus, Retrovirus and Modified Herpes Simplex Virus}, Non-Viral Vectors-Based Gene Therapy {Electroporation, Gene Gun, Liposomes and Naked DNA}, CRISPR/Cas9 Technology), Therapy Type (Acute Lymphoblastic Leukemia (ALL), Inherited Retinal Disease, Large B-Cell Lymphoma, ADA-SCID, Melanoma (lesions), Beta-Thalassemia Major/SCD, Head & Neck Squamous Cell Carcinoma, Peripheral Arterial Disease, Spinal Muscular Atrophy (SMA) and Others), Therapeutic Area (Oncology, Neurological Disorders, Genetic Disorders, Cardiovascular Disorders and Ophthalmic Disorders), End User (Hospitals and Clinics, Biopharmaceutical Companies and Research Institutes), & Region - Global Forecast to 2030"

Gene Therapy Market was valued USD 9.42 Billion in 2023 and projected to reach USD 38.33 Billion by 2030, growing at a CAGR of 22.2% during the forecast period of 2023-2030.

Download Sample Pages - https://www.marketdigits.com/request/sample/277

Browse in-depth TOC on Gene Therapy Market

• 324 - Tables
• 56 - Figures
• 370 - Pages

Market Overview: The Gene Therapy Market is experiencing robust growth and transformative advancements, driven by a confluence of factors shaping the landscape of modern medicine. With an increasing prevalence of chronic diseases and genetic disorders globally, gene therapy has emerged as a groundbreaking solution that holds the potential to revolutionize treatment paradigms. This market is characterized by a dynamic interplay of technological innovation, research and development endeavors, and a growing acceptance of personalized medicine. The focus on precision therapeutics, coupled with a deepening understanding of genomics, has propelled the field forward, leading to a surge in clinical trials and the commercialization of gene-based treatments. Major pharmaceutical companies, biotech firms, and academic institutions are actively contributing to the market's expansion, fostering collaborations and strategic partnerships. Regulatory approvals for some gene therapies have marked significant milestones, providing impetus to further investments and creating a compelling environment for the continued evolution of the Gene Therapy Market. The intersection of scientific progress, therapeutic potential, and market dynamics positions gene therapy as a pivotal force in shaping the future of healthcare.

Market Dynamics

Drivers:

• Growing government support and funding
• Rising demand for personalized medicine
• Increasing adoption of personalized medicine

Opportunities:

• Development of next-generation gene delivery vectors
• Utilizing gene editing tools for therapeutic applications
• Expanding gene therapy manufacturing capabilities

North America dominates the market for Gene Therapy.

North America emerged as the leading market, commanding a substantial 67.56% share of the total revenue. Projections indicate that this region is poised to solidify its position as the primary hub for routine gene therapy manufacturing, both in terms of approval numbers and revenue generation throughout the forecast period. The market is anticipated to benefit from heightened research and development investments by both major industry players and smaller enterprises dedicated to crafting optimal therapeutic drugs. These developments are expected to contribute significantly to the continued growth and advancement of the Gene Therapy Market.

The market is experiencing momentum due to rising government investments and the escalating incidence of targeted diseases. As per data from the Spinal Muscular Atrophy Foundation, in 2020, spinal muscular atrophy impacted a notable population of 10,000 to 25,000 children and adults in the United States. This prevalence underscores the significance of addressing rare diseases, and it contributes to the market's growth trajectory.

Europe is expected to demonstrate the highest growth rate among regional segments. This can be attributed to the region's sizable population facing unmet medical needs and a rising demand for innovative technologies to address increasingly common but rare diseases.

The Asia Pacific market, specifically in the commercial application of genetic therapies, is poised for substantial growth during the forecast period. This can be ascribed to factors such as the ready availability of resources, the local presence of major companies, and heightened government investments in the region.

Top Key Players covered in the market report:

• Regenxbio, Inc.
• xford BioMedica plc
• Dimension Therapeutics, Inc.
• Bristol-Myers Squibb Company
• SANOFI
• pplied Genetic Technologies Corporation
• F. Hoffmann-La Roche Ltd
• Bluebird Bio, Inc.
• Novartis AG
• Taxus Cardium Pharmaceuticals Group, Inc. (Gene Biotherapeutics)
• UniQure N.V.
• Shire Plc
• Cellectis S.A.
• Sangamo Therapeutics, Inc
• Orchard Therapeutics
• Gilead Lifesciences, Inc.
• BENITEC BIOPHARMA
• Sibiono GeneTech Co., Ltd
• Shanghai Sunway Biotech Co., Ltd.
• Gensight Biologics S.A.
• Transgene
• Calimmune, Inc.
• Epeius Biotechnologies Corp.
• Astellas Pharma Inc.
• American Gene Technologies
• BioMarin Pharmaceuticals Inc.

More for Information - Inquire Now!

Segmentations Analysis of Gene Therapy Market: -

• By Technology
• By Therapy Type
• By Therapeutic Area
• By End User
• By Region

About us:

MarketDigits is one of the leading business research and consulting companies that helps clients to tap new and emerging opportunities and revenue areas, thereby assisting them in operational and strategic decision-making. We at MarketDigits believe that a market is a small place and an interface between the supplier and the consumer, thus our focus remains mainly on business research that includes the entire value chain and not only the markets.

Contact Us: Email: sales@marketdigits.com